Loading
A phase 2 trial of retlirafusp alfa in colorectal cancer, run by Fudan University, not yet recruiting.
SHR-1701 Combined with SHR2554 and BP102 for MCRC is a phase 2, interventional study registered as NCT06679673 by Fudan University, with a registry enrolment figure of 20 participants, started 2024-12 and due to reach its primary completion in 2025-12. Interventions recorded: SHR-1701; BP102; SHR2554. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: "* Histological confirmed metastatic colorectal cancer;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.